![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Sofosbuvir/Velpatasvir Plus Voxilaprevir for 6, 8, or 12 Weeks in Genotype 1-6 HCV-infected Patients:
An Integrated Analysis of Safety and Efficacy from Two Phase 2 Studies
|
|
|
Reported by Jules Levin
ID Week 2016 Oct 26-30 New Orleans  
R Nahass1, E Lawitz2, I Jacobson3, P Kwo4, M Nguyen5, JC Yang6, LM Stamm6, S Lu6, H Dvory-Sobol6, S Naik6, J Llewellyn6, DM Brainard6, JG McHutchison6, M Curry7, K Kowdley8, N Reau9, EJ Gane10  
1ID Care, Hillsborough, New Jersey; 2Texas Liver Institute, San Antonio, Texas; 3Mount Sinai Beth Israel, New York, New York; 4Indiana University School of Medicine, Indianapolis, Indiana; 5Stanford University, Stanford, California; 6Gilead Sciences, Inc., Foster City, California; 7Beth Israel Deaconess Medical Center, Boston, Massachusetts; 8Swedish Medical Center, Seattle, Washington; 9Rush University Medical Center, Chicago, Illinois; 10Auckland Clinical Studies Ltd, Auckland, New Zealand
![HIV1](../images/110316/110316-4/HIV1.gif)
![HIV2](../images/110316/110316-4/HIV2.gif)
![HIV3](../images/110316/110316-4/HIV3.gif)
![HIV4](../images/110316/110316-4/HIV4.gif)
![HIV5](../images/110316/110316-4/HIV5.gif)
![HIV6](../images/110316/110316-4/HIV6.gif)
![HIV7](../images/110316/110316-4/HIV7.gif)
![HIV8](../images/110316/110316-4/HIV8.gif)
![HIV9](../images/110316/110316-4/HIV9.gif)
![HIV10](../images/110316/110316-4/HIV10.gif)
![HIV11](../images/110316/110316-4/HIV11.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|